Literature DB >> 3929463

Osteosarcomas and Ewing's sarcomas. Comparative immunocytochemical investigation of filamentous proteins and cell membrane determinants.

T Löning, J Liebsch, G Delling.   

Abstract

Primary malignant bone tumors, osteosarcomas (9 cases), and Ewing's sarcomas (10 cases) were examined for their reactivities with monoclonal and polyclonal antibodies against filamentous proteins and cell membrane determinants of the lymphoid and macrophage marker series. The reactivity of antibodies was studied on snap-frozen tissue probes by using a triple layer immunoperoxidase method. Osteosarcomas were positive for vimentin and, in part, for HLA-DR. Other types of intermediate-sized filaments were not detected in tumour cells. In a small number of cases (2/9) tumour cells were reactive with antibodies of the macrophage series (Leu M2). In Ewing's sarcomas, vimentin and HLA-DR was also demonstrated. It was particularly interesting that Leu M2 staining was found in the majority of cases (8/10). The staining pattern supports the assumption that this peculiar tumour is of mesenchymal (monocyte/macrophage) histogenesis. It was evident from the present study that, in primary osteogenic tumors, none of the examined tumour "markers" were as distinctive as they are for bone metastases. Nevertheless, the reactivity of Ewing's sarcoma cells with monoclonal antibodies of the Leu M2 type throws some highlights on the, as yet, obscure histogenesis of the neoplasm and may be of diagnostic value in conjunction with the known light and electron microscope features of the tumour.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3929463     DOI: 10.1007/bf00710657

Source DB:  PubMed          Journal:  Virchows Arch A Pathol Anat Histopathol        ISSN: 0174-7398


  29 in total

1.  [Immunohistochemical methods in the diagnosis of soft tissue tumors].

Authors:  P Meister
Journal:  Pathologe       Date:  1984-03       Impact factor: 1.011

2.  Ulex europaeus I lectin as a marker for tumors derived from endothelial cells.

Authors:  M Miettinen; H Holthofer; V P Lehto; A Miettinen; I Virtanen
Journal:  Am J Clin Pathol       Date:  1983-01       Impact factor: 2.493

Review 3.  The use of monoclonal anti-T cell antibodies to study T cell imbalances in human diseases.

Authors:  M A Bach; J F Bach
Journal:  Clin Exp Immunol       Date:  1981-09       Impact factor: 4.330

4.  Localization of factor VIII-related antigen in vascular endothelial cells using an immunoperoxidase method.

Authors:  K Mukai; J Rosai; W H Burgdorf
Journal:  Am J Surg Pathol       Date:  1980-06       Impact factor: 6.394

5.  Molecular recognition and the future of monoclonal antibodies.

Authors:  D Lane; H Koprowski
Journal:  Nature       Date:  1982-03-18       Impact factor: 49.962

6.  Distribution of antigens defined by OKB monoclonal antibodies on benign and malignant lymphoid cells and on nonlymphoid tissues.

Authors:  D M Knowles; B Tolidjian; C C Marboe; R S Mittler; M A Talle; G Goldstein
Journal:  Blood       Date:  1984-04       Impact factor: 22.113

7.  Ulex europaeus I lectin as a marker for vascular endothelium in human tissues.

Authors:  H Holthöfer; I Virtanen; A L Kariniemi; M Hormia; E Linder; A Miettinen
Journal:  Lab Invest       Date:  1982-07       Impact factor: 5.662

8.  Differential diagnosis of chordoma, chondroid, and ependymal tumors as aided by anti-intermediate filament antibodies.

Authors:  M Miettinen; V P Lehto; D Dahl; I Virtanen
Journal:  Am J Pathol       Date:  1983-08       Impact factor: 4.307

9.  Factor VII related antigen as an endothelial cell marker in benign and malignant diseases.

Authors:  M Sehested; K Hou-Jensen
Journal:  Virchows Arch A Pathol Anat Histol       Date:  1981

10.  Monoclonal antibodies defining serologically distinct HLA-D/DR related Ia-like antigens in man.

Authors:  L M Nadler; P Stashenko; R Hardy; J M Pesando; E J Yunis; S F Schlossman
Journal:  Hum Immunol       Date:  1981-02       Impact factor: 2.850

View more
  6 in total

1.  [New morphologic findings in malignant bone tumors].

Authors:  G Delling
Journal:  Langenbecks Arch Chir       Date:  1987

2.  Immunologic characterization of Ewing's sarcoma using mesenchymal and neural markers.

Authors:  S Lizard-Nacol; G Lizard; E Justrabo; C Turc-Carel
Journal:  Am J Pathol       Date:  1989-11       Impact factor: 4.307

3.  Ewing's sarcoma. A retrospective study of histological and immunohistochemical factors and their relation to prognosis.

Authors:  S Daugaard; C Kamby; L M Sunde; O Myhre-Jensen; T Schiødt
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1989

4.  Immunocytochemical analysis of Ewing's tumors. Patterns of expression of intermediate filaments and desmosomal proteins indicate cell type heterogeneity and pluripotential differentiation.

Authors:  R Moll; I Lee; V E Gould; R Berndt; A Roessner; W W Franke
Journal:  Am J Pathol       Date:  1987-05       Impact factor: 4.307

5.  Dedifferentiated chondrosarcoma of bone. An immunohistochemical and lectin-histochemical study.

Authors:  M R Wick; G P Siegal; S E Mills; R C Thompson; D Sawhney; R E Fechner
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1987

6.  High Expression of Complement Component 5 (C5) at Tumor Site Associates with Superior Survival in Ewing's Sarcoma Family of Tumour Patients.

Authors:  Suvi Savola; Arto Klami; Samuel Myllykangas; Cristina Manara; Katia Scotlandi; Piero Picci; Sakari Knuutila; Jukka Vakkila
Journal:  ISRN Oncol       Date:  2011-10-02
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.